Blow to Orion as deramciclane fails in Phase III anxiety studies

Related Companies

Orion Pharma of Finland and partner Pharmacia have decided todiscontinue the development of deramciclane…

Orion PharmaPharmacia

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days

alt

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £77 per month or £820 per year

alt

  • No-limits access to our site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top